Temodar

Mycosis Fungoides, Advance Directives, Radiotherapy + 11 more
Treatment
20 Active Studies for Temodar

What is Temodar

TemozolomideThe Generic name of this drug
Treatment SummaryTemozolomide is a medication used to treat malignant brain tumors such as grade III anaplastic astrocytoma and grade IV glioblastoma. It works by breaking down into a highly reactive methyl diazonium cation, which then causes damage to the DNA in the cancer cells, leading to their death. Temozolomide was approved by the FDA in 1999 and is available as an oral capsule or an intravenous injection. It is also known under the brand name TEMODAR.
Temodaris the brand name
image of different drug pills on a surface
Temodar Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Temodar
Temozolomide
1999
164

Effectiveness

How Temodar Affects PatientsTemozolomide is a drug that works by damaging the DNA of cells, leading to cell death. This treatment is linked to reduced blood cell counts, especially in older and female patients. Before starting the therapy, patients must have a certain level of blood cells, and this must be checked weekly during treatment. Additionally, there have been cases of Myelodysplastic Syndrome and other forms of cancer reported after taking temozolomide. Pneumonia may also occur during treatment, so patients should take preventative measures. Lastly, temozolomide has been linked to severe liver damage, so liver tests should be
How Temodar works in the bodyTemozolomide is a drug used to treat glioblastoma, the most common form of brain cancer. It works by creating methyl groups that attach to DNA and cause it to malfunction. Glioblastoma cells with low levels of a certain enzyme, called MGMT, are sensitive to temozolomide. The drug also affects the immune system by reducing the number of immune-suppressing cells found in the tumor, making it easier for the body's natural defenses to fight the cancer.

When to interrupt dosage

The recommended dosage of Temodar is contingent upon the identified condition, for example Refractory Ewing Sarcoma, melanoma and Glioblastoma. The volume of dosage fluctuates according to the technique of delivery (e.g. Capsule or Intravenous) detailed in the table beneath.
Condition
Dosage
Administration
Disease Progression
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Glioblastoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Nitrosourea treatment
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Procarbazine treatment
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Sarcoma, Ewing
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Anaplastic astrocytoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Radiotherapy
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Mycosis Fungoides
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
melanoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Primary Central Nervous System Lymphoma (PCNSL)
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Soft Tissue Sarcoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Neuroblastoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Temodar Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Temozolomide may interact with Pulse Frequency
There are 20 known major drug interactions with Temodar.
Common Temodar Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Acteoside.
Temodar Toxicity & Overdose RiskTaking too much temozolomide can lead to a decrease in white and red blood cells, fever, infection, and in some cases death. One person who took 2000mg/day for five days experienced a decrease in all blood cells, fever, and organ failure, which eventually lead to death. Those who overdose should be closely monitored and given supportive care as needed.
image of a doctor in a lab doing drug, clinical research

Temodar Novel Uses: Which Conditions Have a Clinical Trial Featuring Temodar?

217 active clinical trials are investigating the potential of Temodar in providing therapeutic benefit for melanoma, Primary Central Nervous System Lymphoma (PCNSL) and Glioblastoma Patients.
Condition
Clinical Trials
Trial Phases
Anaplastic astrocytoma
0 Actively Recruiting
Mycosis Fungoides
6 Actively Recruiting
Phase 2, Phase 1
Procarbazine treatment
0 Actively Recruiting
melanoma
0 Actively Recruiting
Soft Tissue Sarcoma
58 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
Advance Directives
0 Actively Recruiting
Glioblastoma
66 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3
Disease Progression
0 Actively Recruiting
Neuroblastoma
0 Actively Recruiting
Sarcoma, Ewing
0 Actively Recruiting
Nitrosourea treatment
0 Actively Recruiting
Primary Central Nervous System Lymphoma (PCNSL)
15 Actively Recruiting
Phase 1, Phase 2
Advance Directives
0 Actively Recruiting
Radiotherapy
6 Actively Recruiting
Phase 1, Not Applicable, Phase 3, Phase 2

Temodar Reviews: What are patients saying about Temodar?

5Patient Review
1/13/2012
Temodar for Malignant Brain Tumor Glioblastoma
After my brother's tumor was discovered in 2007, he had surgery to remove 80% of it. He then did six months of radiation and temodar therapy, which put him into remission for four years. However, last month the tumor started growing again. We're hopeful that the combination treatment will work again and buy us some more time.
5Patient Review
1/18/2015
Temodar for Cancer of Pancreas Islet Cells
I was diagnosed in 2001 with an unresectable neuroendocrine tumor. I've been on Sandostatin for 7 years and Afinitor for 5 years. So far, I've done 9 months of Temodar treatment, which has been the easiest to take of all the treatments I've had. The biggest side effects are severe constipation and fatigue. My first two series of MRIs showed shrinkage and no spread. I'll be doing my third MRI next week.
5Patient Review
7/25/2021
Temodar for Malignant Brain Tumor Glioblastoma
I was diagnosed with GBM4 on 05/02/2021 and had a craniotomy on 05/05/2021. I started my 6 weeks of radiation and 42 days of Temodar immediately afterwards, and never experienced any negative symptoms or side effects. They did say that my experience was rare, but I hope that many others will have a similar one.
5Patient Review
1/15/2013
Temodar for Malignant Brain Tumor Glioblastoma
I was diagnosed in April 2012 and had surgery to remove a brain tumor on June 15, 2012. I started Temodar 28 days after the surgery and have been on it for seven cycles now. I go in for bloodwork every 21 days and an MRI every cycle. So far, the MRIs have shown no new growth.
4.7Patient Review
1/31/2012
Temodar for Malignant Brain Tumor Glioblastoma
My doctor removed as much of the tumor as possible, but unfortunately it started growing back a few months later. They opted for Temodar and, so far, it seems to be working; my aggressive tumor hasn't grown at all in the year I've been on the treatment. The only downside is that I get tired after the five day cycles each month, but it's a small price to pay for peace of mind.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about temodar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of chemo is Temodar?

"This medication is used to treat brain cancer by slowing the growth of cancer cells."

Answered by AI

Is Temodar chemotherapy?

"Temodar is a chemotherapy drug that is used in combination with radiation therapy to treat certain types of brain tumors in adults. Temodar is sometimes given after other cancer medications have been tried without successful treatment of the tumor."

Answered by AI

What is Temodar used to treat?

"The chemotherapy medication Temodar is primarily prescribed for gliomas, but can also be used for a variety of brain tumor types. The dosage given varies depending on the treatment plan--it can be prescribed at a lower dose to be taken daily during radiation therapy, or at a higher dose to be taken only five days per month."

Answered by AI

Do you lose hair with Temodar?

"If you experience hair loss while taking this medication, it is most likely to occur within 3-4 weeks of starting the treatment. However, it is possible to experience hair loss earlier. This side effect is temporary and your hair will grow back once you finish taking the medication."

Answered by AI

Clinical Trials for Temodar

Have you considered Temodar clinical trials? We made a collection of clinical trials featuring Temodar, we think they might fit your search criteria.
Have you considered Temodar clinical trials? We made a collection of clinical trials featuring Temodar, we think they might fit your search criteria.
Have you considered Temodar clinical trials? We made a collection of clinical trials featuring Temodar, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top